Dr. James D. Watson Opens Pall Corporation Life Sciences Facility.

Business Editors and Medical/Health Writers

EAST HILLS, N.Y.--(BW HealthWire)--June 25, 2001

James D. Watson PhD, USA, Nobel Prize winner for discovering the structure of DNA, was the keynote speaker at the opening of Pall Corporation's (NYSE: PLL) new Life Sciences laboratory complex. The new laboratory provides a complete package of analytical, process and validation capabilities in the fast growing biotechnology market place.

Dr. Watson, who provided the keynote address, was joined by Dr. Charles Lutsch, Aventis Pasteur, France and Dr. David Sherwood, Lonza Biologics, UK and other leading biotechnology companies at the opening ceremony. Dr. Watson, a member of Pall's Board of Directors, spoke of the importance of the laboratory to support the remarkable strides being made in drug discovery research for cancer, Alzheimer's and other diseases.

Eric Krasnoff, Pall's Chairman and CEO, said, "We are highly focused on biotechnology, genomics and proteomics. Pall has invested in key technologies to accelerate our customers' ability to bring new products to market faster. The opening of this laboratory, just one part of our commitment to provide the full spectrum of filtration, purification and separations technologies for our life sciences customers." Pall's Life Sciences business represents about $600 million in sales, roughly half of Pall Corporation's revenues.

The new suite of laboratories are located in Pall's Portsmouth, England facility. It is designed to culture and handle genetically modified organisms and products including both mammalian and microbial cell lines. The laboratory enables Pall to assist global customers in the development and optimization of separation systems used to manufacture new drugs. Enhanced validation packages are offered through the laboratory to meet the latest regulatory requirements for new technologies.

Pall is the leader in the rapidly growing filtration, separations and purification industry. Pall's business is organized around two broad markets: Life Sciences and Industrial, and has annual sales of over $1.2 billion. The company provides leading-edge products for high-growth applications such as genomics, proteomics and biotechnology; and in transfusion medicine; semiconductor; water; aerospace and a host of other industries. The Company is headquartered in East Hills, New York and has operations in more than 30 countries. Further information can be found at http://www.pall.com.

This release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current Company expectations and are subject to risks and uncertainties, which could cause actual results to differ materially. Such risks and uncertainties include, but are not limited to: fluctuations in foreign currency exchange rates; regulatory approval and market acceptance of new technologies; changes in product mix and product pricing and in interest rates and cost of raw materials; the Company's success in enforcing its patents and protecting its proprietary products and manufacturing techniques; global and regional economic conditions and legislative, regulatory and political developments; and domestic and international competition in the Company's global markets. Additional information regarding these and other factors is available on the Web at http://www.pall.com and is included in the Company's reports filed with the U.S. Securities and Exchange Commission. Copies of such reports can be obtained, without charge, at: http://www.sec.gov.

For media inquiries, contact Patrice Radowitz, 516-484-3600 ext. 6111, e-mail [e-mail]. For investor inquiries, contact Diane Foster, 516-484-3600 ext. 6109, e-mail [e-mail].